| 陈 雪,初 明,杨 珂,阴凯麟,何嘉勰,徐 兰,焦运燊,丁羚昱,刘彦辰,初正云,王月丹.转录因子二聚化配体3（TFDP3）在乳腺癌组织中的表达及其与乳腺癌分子分型的相关性研究[J].现代生物医学进展英文版,2017,17(1):1-6. |
| 转录因子二聚化配体3（TFDP3）在乳腺癌组织中的表达及其与乳腺癌分子分型的相关性研究 |
| The Expression of TFDP3 in Breast Cancer and Its Role of Breast Cancer Molecular Classification |
| Received:May 12, 2016 Revised:May 26, 2016 |
| DOI：10.13241/j.cnki.pmb.2017.01.001 |
| 中文关键词: 乳腺癌 转录因子二聚化配体3 癌睾丸抗原 HER-2 分子分型 |
| 英文关键词: Breast cancer TFDP3 Cancer testis antigen HER-2 Molecular typing |
| 基金项目:国家自然科学基金项目（81172884）；北京市自然科学基金项目（7162099）；国家基础科学人才培养基金项目（J1030831/ J0108）；深圳市2015年科技研发资金基础研究项目；北京大学创新人才培养计划，北京大学医学部新教师启动基金项目（BMU0239） |
|
| Hits: 1257 |
| Download times: 1505 |
| 中文摘要: |
| 摘要 目的：本研究旨在分析总结癌-睾丸抗原TFDP3在乳腺癌中的表达规律，探究TFDP3表达与乳腺癌分型及发病进程关系。方法：通过对不同分型及分期的乳腺癌组织切片进行免疫组化检测，分析TFDP3在其中的表达情况，并结合样本来源患者的临床信息，对TFDP3的表达与乳腺癌分子分型、分期及预后的相关性进行统计分析。同时，通过Western Blot检测了5种乳腺癌细胞系（MDA-MB-231、MCF-7、SK-BR-3、T47D及MCF-10A）中TFDP3的表达情况，并通过细胞免疫荧光实验，检测TFDP3在细胞中的定位。结果：TFDP3在已检测的乳腺癌样本中的表达率为49%。乳腺癌临床分子分型标记物HER2的表达与TFDP3的表达呈正相关，但乳腺癌的分期、临床病理分型以及临床分子分型标记物ER、PR的表达均与肿瘤组织中TFDP3的表达无相关性。结论：TFDP3在各在乳腺癌组织中高表达，其表达量与HER2的表达量呈正性相关。这为研究已TFDP3为靶点的乳腺癌免疫治疗，提供了新的依据。 |
| 英文摘要: |
| ABSTRACT Objective: The object of this study is to analysis the expression of cancer testis antigen TFDP3 in breast cancer, to ex- plore the correlation between TFDP3 and development of breast cancer. Methods: The expression of TFDP3 was detected in pathological section of tumor tissues from patients with breast cancer using immunohistochemical method. And we analyzed the data with clinical in- formation of patients to discover the correlation of TFDP3 and the molecular classification of breast cancer. We also detected the expres- sion of TFDP3 protein in five breast cancer cell lines, including MDA-MB-231, MCF-7, SK-BR-3, T47D and MCF-10A, using Western Blot. Then we verified the location of TFDP3 protein in cells through immunofluorescence method. Results: TFDP3 is greatly and broadly expressed in many cell lines and breast cancer tissues, such as breast, lymph node, hypothyroid, appendix and so on, while TFDP3 is 49% percent positive in breast cancer. The expression of TFDP3 is unrelated with clinical stage, pathology type and molecular classification of breast cancer, but related with special tumor marker HER2. Conclusion: TFDP3 highly expresses in breast cancer is related with the ex- pression of HER2. It suggests that TFDP3 be a new potential target molecule of immunotherapy for breast cancer. |
|
View Full Text
View/Add Comment Download reader |
| Close |
